Mankind Pharma: Jefferies maintains a Buy on Mankind Pharma with a Target Price of ₹3,000, citing expectations of double-digit India growth led by recovery in acute therapies, sustained chronic therapy strength and wider BSV coverage, high-teens export growth driven by deeper penetration and new markets, and medium-to-long term upside from R&D investments including in-house assets.

 03 Jun 2026 08:46 AM

Mankind Pharma: Jefferies maintains a Buy on Mankind Pharma with a Target Price of ₹3,000, citing expectations of double-digit India growth led by recovery in acute therapies, sustained chronic therapy strength and wider BSV coverage, high-teens export growth driven by deeper penetration and new markets, and medium-to-long term upside from R&D investments including in-house assets.

Mankind Pharma: Co Aims for High Teen Growth Instead of 50-60% Growth in Future. - Concall Update

 20 May 2026 12:51 PM

Mankind Pharma: Co Aims for High Teen Growth Instead of 50-60% Growth in Future. - Concall Update

Mankind Pharma: Management Predicts Strong FY 2027 Growth With Over 10% Revenue Increase And EBITDA Margins Of 25.5% To 26.5%.

 20 May 2026 12:30 PM

Mankind Pharma: Management Predicts Strong FY 2027 Growth With Over 10% Revenue Increase And EBITDA Margins Of 25.5% To 26.5%.

Mankind Pharma: Expects Double-Digit Revenue Growth From Global Operations in FY27 - Concall Update

 20 May 2026 12:39 PM

Mankind Pharma: Expects Double-Digit Revenue Growth From Global Operations in FY27 - Concall Update

Mankind Pharma: Expects FY27 EBITDA Margins Between 2.5% And 26.5% - Concall Update.

 20 May 2026 12:39 PM

Mankind Pharma: Expects FY27 EBITDA Margins Between 2.5% And 26.5% - Concall Update.

Mankind Pharma: Gets Approval For Extra Investment Of Up To 5 Billion Rupees In Mankind Medicare In Multiple Tranches.

 19 May 2026 07:33 PM

Mankind Pharma: Gets Approval For Extra Investment Of Up To 5 Billion Rupees In Mankind Medicare In Multiple Tranches.

MANKIND PHARMA: Q4 CONS NET PROFIT 5.6B RUPEES VS 4.25B (YOY) || Q4 REVENUE 34.4B RUPEES VS 30.8B (YOY)

 19 May 2026 07:28 PM

MANKIND PHARMA: Q4 CONS NET PROFIT 5.6B RUPEES VS 4.25B (YOY) || Q4 REVENUE 34.4B RUPEES VS 30.8B (YOY)

MANKIND PHARMA: Q4 EBITDA 9.3B RUPEES VS 6.84B (YOY) || Q4 EBITDA MARGIN 27% VS 22.22% (YOY)

 19 May 2026 07:28 PM

MANKIND PHARMA: Q4 EBITDA 9.3B RUPEES VS 6.84B (YOY) || Q4 EBITDA MARGIN 27% VS 22.22% (YOY)

Mankind Pharma: Morgan Stanley maintains an Overweight on Mankind Pharma with a Target Price of ₹2500, citing improving execution, recovery in BSV business, ongoing deleveraging, stronger MR activity and productivity gains, with management disruptions seen as transitory and the company offering superior risk-reward and valuation support versus other domestic formulation peers.

 08 May 2026 08:53 AM

Mankind Pharma: Morgan Stanley maintains an Overweight on Mankind Pharma with a Target Price of ₹2500, citing improving execution, recovery in BSV business, ongoing deleveraging, stronger MR activity and productivity gains, with management disruptions seen as transitory and the company offering superior risk-reward and valuation support versus other domestic formulation peers.

Mankind Pharma: Board Approves Closing Mankind Pharma Lanka, With No Ongoing Business Due To New Rules

 13 Apr 2026 03:28 PM

Mankind Pharma: Board Approves Closing Mankind Pharma Lanka, With No Ongoing Business Due To New Rules

Mankind Pharma: Morgan Stanley on Mankind Pharma Overweight (Initiated), Target Price Rs 2500 as 11% revenue CAGR, ~25% EPS CAGR, domestic recovery, Bharat Serums and Vaccines optionality and 11–12% IPM growth drive superior risk-reward.

 27 Mar 2026 09:03 AM

Mankind Pharma: Morgan Stanley on Mankind Pharma Overweight (Initiated), Target Price Rs 2500 as 11% revenue CAGR, ~25% EPS CAGR, domestic recovery, Bharat Serums and Vaccines optionality and 11–12% IPM growth drive superior risk-reward.

Mankind Pharma: Purchases Rivotril Brand in India To Boost CNS Treatments; Gains Exclusive Rights For Production, Sales, And Distribution; Enhances Options For Neurological Care.

 18 Mar 2026 10:02 AM

Mankind Pharma: Purchases Rivotril Brand in India To Boost CNS Treatments; Gains Exclusive Rights For Production, Sales, And Distribution; Enhances Options For Neurological Care.

Mankind Pharma: Search And Seizure/Inspection Operation Conducted By Gst Department At Bharat Serums And Vaccines || Unit Operations Continued As Usual During Inspection

 09 Feb 2026 03:04 PM

Mankind Pharma: Search And Seizure/Inspection Operation Conducted By Gst Department At Bharat Serums And Vaccines || Unit Operations Continued As Usual During Inspection

MANKIND PHARMA: OPERATION CONDUCTED FROM FEBRUARY 03 TO FEBRUARY 08, 2026 || BUSINESS OPERATIONS OF BSV CONTINUED AS USUAL DURING SEARCH

 09 Feb 2026 03:05 PM

MANKIND PHARMA: OPERATION CONDUCTED FROM FEBRUARY 03 TO FEBRUARY 08, 2026 || BUSINESS OPERATIONS OF BSV CONTINUED AS USUAL DURING SEARCH

MANKIND PHARMA: Q3 REVENUE 36B RUPEES VS 32B (YOY)

 03 Feb 2026 04:29 PM

MANKIND PHARMA: Q3 REVENUE 36B RUPEES VS 32B (YOY)

MANKIND PHARMA: Q3 EBITDA 9.19B RUPEES VS 8.30B (YOY) || Q3 EBITDA MARGIN 25.76% VS 25.7% (YOY)

 03 Feb 2026 04:29 PM

MANKIND PHARMA: Q3 EBITDA 9.19B RUPEES VS 8.30B (YOY) || Q3 EBITDA MARGIN 25.76% VS 25.7% (YOY)

MANKIND PHARMA: Q3 CONS NET PROFIT 4.1B RUPEES VS 3.8B (YOY); EST 5.1B

 03 Feb 2026 04:29 PM

MANKIND PHARMA: Q3 CONS NET PROFIT 4.1B RUPEES VS 3.8B (YOY); EST 5.1B

Mankind Pharma: Co To Consider Q3 Results On Feb 3

 09 Jan 2026 11:56 AM

Mankind Pharma: Co To Consider Q3 Results On Feb 3